Close this search box.

Tilray Shares Jump 15% as Losses Narrow and Sales Beat Estimates

Tilray has reported narrowing losses during its fourth quarter while sales came in well above analyst estimates, leading to a bump in stock price.

The Canadian cannabis giant published its full-year results for the fiscal year 2023 on Wednesday, reporting a net loss for the year of $1.4bn.

Despite this, the results were viewed relatively favourably by investors due to the $119.8m loss it booked in Q4, which represented a significant improvement on the $457.8m loss recorded in the same period a year earlier.

While the Q4 loss came well above analyst expectation, its revenue for the period increased by 20% year-on-year from $153.3m to $184.2m, significantly outperforming expectations.

Tilray’s EBITDA for the quarter also came above analysts’ predictions of $20m, at $22.2m.

READ MORE: Incannex To Relocate To US From Australia And List Shares On NASDAQ

Although cannabis net revenues also performed strongly in Q4, rising from $53m to $64m year-on-year, Tilray’s sales performance on an annual basis was not so positive.

For the fiscal year 2023, cannabis revenues were down 7.1% to $220.3m, while distribution sales and wellness sales also decreased by 0.3% and 11% respectively.

In Canada, the company’s medical cannabis sales dropped by 17% to $25m year-on-year, while recreational sales saw a slight uptick of 2.4% to $214.3m.

Wholesale cannabis sales and international cannabis sales both fell significantly, by 79% and 19% respectively.

Looking ahead, Tilray said it expects to achieve EBITDA of between $68m and $78m in the upcoming fiscal year.

Related Posts

Related Posts


Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you


Browse by Tags




© 2023 Prohibition Holdings Ltd. All Rights Reserved.


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?